CLINICAL TRIAL

Rituximab for Lymphoma

1 Prior Treatment
Grade I
Refractory
Relapsed
Waitlist Available · 18+ · All Sexes · Saint Louis, MO

This study is evaluating whether a new drug combination can help treat follicular lymphoma.

See full description

About the trial for Lymphoma

Eligible Conditions
Follicular Lymphoma ( FL) · Lymphoma, Follicular · Lymphoma

Treatment Groups

This trial involves 3 different treatments. Rituximab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Experimental Group 1
Avelumab
DRUG
+
Rituximab
DRUG
+
PF04518600
DRUG
Experimental Group 2
Avelumab
DRUG
+
Rituximab
DRUG
+
Utomilumab
DRUG
Experimental Group 3
Rituximab
DRUG
+
Utomilumab
DRUG
+
PF04518600
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Avelumab
FDA approved
Rituximab
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Lymphoma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patients with active histologic transformation are excluded. Relapsed/refractory patients with prior transformation may be included as long as there is no evidence of transformation at the time of study entry by pathology, imaging, or clinical status
Organ function impairment due to disease involvement, including cytopenias due to marrow involvement (WBC <1.5x109/L; absolute neutrophil count [ANC] <1.0x109/L, Hgb <10g/dL; platelets <100x109/L)
Relapsed or primary refractory after at least one line of therapy including anti-CD-20 monoclonal antibody treatment (part A) or;
Has had no previous anti-lymphoma therapy other than corticosteroids or radiotherapy (part B).
Constitutional symptoms
Maximum diameter of disease > 7cm
-->3 nodal sites of involvement
Risk of local compressive symptoms
Splenomegaly (craniocaudal diameter > 16cm on CT imaging)
Symptomatic adenopathy
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Rituximab will improve 1 primary outcome and 11 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of 2 years.

Complete response rate
2 YEARS
Lyric criteria
2 YEARS
Time to Next Treatment Response Duration
2 YEARS
2 YEARS
Rate of Adverse events leading to discontinuation due to toxicity
2 YEARS
2 YEARS
Partial Response Rate
2 YEARS
Lugano criteria
2 YEARS
Rate of Grade 3 and higher toxicities
2 YEARS
Related to study treatment
2 YEARS
Overall Survival Rate
2 YEARS
2 YEARS
See More

Who is running the study

Principal Investigator
C. A. J.
Caron A. Jacobson, Principal Investigator
Dana-Farber Cancer Institute

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of lymphoma?

The most common sign of lymphoma is a lump in the neck; most cases are early-stage and are found in the jaw, mouth (lip), or throat.

Anonymous Patient Answer

How many people get lymphoma a year in the United States?

Because the incidence of lymphoma is steadily increasing over the past several decades, it is estimated that lymphoma is currently the second most common cancer among the 65 and older age group in the United States.

Anonymous Patient Answer

What are common treatments for lymphoma?

Collectively, these results indicate that chemotherapy and curative radiation therapy remain the most frequently used treatments for DLBCL. Rituximab may also be of some benefit, particularly in the short-term.

Anonymous Patient Answer

Can lymphoma be cured?

Lymphoma can be cured for some patients; the most likely cures come from the remissions that occur after initial chemotherapy. However, curing lymphoma does not mean that it can be eliminated. The key to avoiding treatment failures is the early identification of lymphoma patients who are most likely to benefit from treatment.

Anonymous Patient Answer

What causes lymphoma?

While no one factor is responsible, there is a strong hereditary component. Multiple myeloma occurs almost exclusively in people who also have a B-cell lymphoma; while no one group of lymphomas has any particular genetic defect, the presence of multiple types of lymphoma within a single patient suggests that multiple genetic abnormalities in cell proliferation may be implicated in the development of lymphoma.

Anonymous Patient Answer

What is lymphoma?

The symptoms of lymphoma in many cases are vague and non-specific. Lymphoma in primary care tends to be classified as a non-lymphoid cancer, and this is at the time of diagnosis and it does not give anything in regard to the lymphoid origin of the malignancy. The management of lymphoma should be similar to that of other cancers insofar as possible.

Anonymous Patient Answer

What is the latest research for lymphoma?

The most recent advances seem to be focused on immunotherapy; in the past 15 years numerous advances in the treatment options have been reported, but no new drugs have been approved. Only small steps have been taken to make the chemotherapy more effective and less toxic. In 2004, researchers identified the first viable human tumor in the body that grew in the lymphatic system and that could remain tumor free after only one injection of chemotherapy. The same researchers are now studying the possibilities of combining tumor-fighting drugs with agents that specifically target the lymphatic system. This new knowledge may lead to personalized treatment for certain cancer types. There also is a need to develop new approaches to chemotherapy, particularly the possibility of chemotherapy-based tumor vaccines.

Anonymous Patient Answer

Who should consider clinical trials for lymphoma?

As a majority of lymphomas do not respond to treatment, most patients will not benefit from current treatment options. Clinical trials are an important tool that can make the diagnosis and treatment choices for lymphoma patients, and may improve outcomes for patients with lymphoma.

Anonymous Patient Answer

Does rituximab improve quality of life for those with lymphoma?

Rituximab did not change HRQOL of patients with NHL. The side effects were similar to those reported in previous studies. Future studies should explore the impact of more targeted agents and/or new therapeutic strategies on HRQOL.

Anonymous Patient Answer

What are the chances of developing lymphoma?

The risk for developing non-Hodgkin's lymphoma varied widely. The cumulative risks of developing non-Hodgkin's lymphoma and diffuse large B-cell lymphoma were higher with age than with gender and other demographic factors.

Anonymous Patient Answer

What are the common side effects of rituximab?

Common rituximab side effects include:\n- fatigue\n- nausea\n- diarrhea\n- fatigue\n- hair loss\n- loss of appetite\n- abdominal pain\n- swelling of the ankles\n- rash\n- rash\n- headache\n- pain in back\n- cough\n\nThere have been some studies done and some side effects reported when it comes to the use of rituximab.

Anonymous Patient Answer

How does rituximab work?

A single dose of rituximab was effective even in this cohort of patients who experienced the side effects described in the previous studies, and the results suggested that the adverse effects are related to the disease, rather than the agent. The improvement in response to induction therapy was not caused by its effects on disease.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Lymphoma by sharing your contact details with the study coordinator.